ASCO 2023 | Future approaches in CRPC: radioligands, CAR-T and bispecifics

Pedro Barata, MD, University Hospitals Seidman Cancer Center, Cleveland, OH, provides an overview of key challenges in the current treatment landscape for men with castration-resistant prostate cancer (CRPC), highlighting the need for durable remission which may be achieved by novel targeted approaches, such as radioligand, CAR-T, and bispecific compounds. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.